SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

April 2019, Volume 5, Issue 5

Focus on Lymphoid Malignancies (Volume 5, Issue 4.1)

March 2019, Volume 5, Issue 4

February 2019, Volume 5, Issue 3

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Is there a genetic risk for familial CLL?

Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL

Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more

Pulling Back the Curtain: Clara Bloomfield, MD

Raising the Barre: Kimberly Stegmaier, MD

Current Issue

April 2019, Volume 5, Issue 5

Meeting Coverage

How Do Patient and Physician Attitudes Drive Choices in Antiplatelet Therapy for Thrombocytopenia?

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Editor`s Corner

The Day I Was Schooled on CME

The Color of Blood and “Exohematology”